Array BioPharma and Biogen Idec have commenced an autoimmune disorder-focused partnership aimed at the discovery and development of inhibitors targeting a novel kinase.
The collaboration target and lead inhibitors were discovered through Array's Kinase-Directed Phenotypic Screening Platform.
“Array has a strong track record in the discovery of novel compounds, and we are delighted to collaborate with them,” said Jo Viney, Ph.D., vice president of immunology research, Biogen Idec. “We are encouraged by the potential of this program to address inflammatory disease and are excited to add it to our immunology research portfolio.”
Under the terms of the agreement, Biogen will be responsible for all aspects of clinical development and commercialization. The agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.
Last week, Array announced the appointment of Nicholas A. Saccomano, Ph.D., as CSO. Dr. Saccomano will play a critical role in expanding the company’s discovery collaboration business.
“I am impressed with the consistent productivity of Array's discovery team, inventing approximately 18 drugs that have advanced into clinical development since the company's inception, as well as its impressive roster of alliance partners,” said Dr. Saccomano. “I look forward to working with this talented team as we look to broaden our collaborative outreach and build on an already outstanding track record of drug discovery.”
Dr. Saccomano replaces Kevin Koch, who resigned as CSO late last year.
